[HTML][HTML] Senolytics improve bone forming potential of bone marrow mesenchymal stem cells from aged mice
NPJ Regenerative medicine, 2021•nature.com
The osteogenic potential of bone marrow mesenchymal stem cells (BMSCs) declines
dramatically with aging. By using a calvarial defect model, we showed that a senolytic
cocktail (dasatinib+ quercetin; D+ Q) improved osteogenic capacity of aged BMSC both in
vitro and in vivo. The study presented a model to assess strategies to improve bone-forming
potential on aged BMSCs. D+ Q might hold promise for improving BMSC function in aged
populations.
dramatically with aging. By using a calvarial defect model, we showed that a senolytic
cocktail (dasatinib+ quercetin; D+ Q) improved osteogenic capacity of aged BMSC both in
vitro and in vivo. The study presented a model to assess strategies to improve bone-forming
potential on aged BMSCs. D+ Q might hold promise for improving BMSC function in aged
populations.
Abstract
The osteogenic potential of bone marrow mesenchymal stem cells (BMSCs) declines dramatically with aging. By using a calvarial defect model, we showed that a senolytic cocktail (dasatinib+quercetin; D + Q) improved osteogenic capacity of aged BMSC both in vitro and in vivo. The study presented a model to assess strategies to improve bone-forming potential on aged BMSCs. D + Q might hold promise for improving BMSC function in aged populations.
nature.com